JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).
B-ALL
DRUG: JY231 Injection
Incidence of adverse events(AE) after infusion, The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included., Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24|Maximal Tolerated Dose(MTD), MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment., Up to 28 days after infusion
Objective Response Rate, Objective Response Rate(ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR)., Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24
This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell(CAR-T cell) therapy in patients with relapsed refractory B-cell Acute Lymphoblastic Leukemia (B-ALL). Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control.